Hyperglycemia and antipsychotic medications

Area of Science:

• Endocrinology
• Psychiatry
• Pharmacology

Background:

• Type 2 diabetes mellitus and impaired glucose tolerance are significant health concerns.
• Antipsychotic treatment is increasingly associated with metabolic disturbances, including diabetes.
• Pre-existing metabolic issues in psychiatric patients can be exacerbated by antipsychotic use.

Purpose of the Study:

• To investigate the association between antipsychotic medications and glucose metabolism.
• To identify specific antipsychotic agents with a higher risk of inducing diabetes.
• To explore the mechanisms linking antipsychotics, weight gain, and dyslipidemia to impaired glucose regulation.

Main Methods:

• Review of clinical reports and controlled studies on antipsychotic use and metabolic changes.
• Analysis of the relationship between specific antipsychotics (e.g., clozapine, olanzapine) and diabetes incidence.
• Examination of the impact of antipsychotics on insulin action, insulin secretion, weight gain, and lipid profiles.

Main Results:

• Antipsychotic treatment is associated with new-onset type 2 diabetes mellitus and diabetic ketoacidosis.
• Chlorpromazine, clozapine, and olanzapine show the strongest association with diabetes and weight gain.
• Antipsychotics can impair glucose regulation, potentially independent of weight gain, and are linked to dyslipidemia.

Conclusions:

• Antipsychotic medications pose a risk for developing type 2 diabetes and related metabolic complications.
• The risk varies among antipsychotic agents, with some requiring closer metabolic monitoring.
• Regular monitoring of weight, plasma glucose, and lipid levels is essential for managing patients on antipsychotics to mitigate iatrogenic risks.